12(90)/2022/DP/NPPA/Div-II भारत सरकार Government of India रसायन एवंउर्वरक मंत्रालयMinistry of Chemicals & Fertilizers औषध विभाग Department of Pharmaceuticals राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण National Pharmaceuticals Pricing Authority

> तीसरी/पांच वीमंजिल 3rd/5th Floor वाई.एम.सी.ए. सांस्कृतिककेंद्र बिल्डिंग YMCA Cultural Center Building 1, जय सिंह रोड़, नयी दिल्ली -110001 1, Jai Singh Road, New Delhi – 110001

दिनांक: 05.06.2024

OFFICE MEMORANDUM

Subject: Fixation of Ceiling Price of I.V. Fluids under Revised Schedule-I (NLEM 2022) of DPCO, 2013 notified vide S.O. No. 5249(E) dated 11.11.2022.

With reference to the Office Memorandum dated 01.02.2023, issued by this office on the above subject, the PTR and MAT values were requested for the month of July, 2022. However, in line with the decision taken by the Authority in its 120th meeting held on 24.01.2024, all the concerned manufacturers / marketing companies are hereby requested to furnish data in respect of Price to Retailer (PTR) and Moving Annual Turnover (MAT) in value terms for the month of **October, 2023** in the format given in**Table 1** along with the Form II/ Form V as well as licenses showing clearly the pack size, type of packaging, etc. The information may be furnished positively within 10 days from the issue of this O.M. in respect of formulations mentioned in **Table 2** for enabling NPPA to take appropriate action based on the available data. The companies are also requested to send the sample of their products to NPPA for the purpose of verification.

Table 1

S. No.	Type of packaging viz Glass/ Non-Glass**	Pack size (in ml) pack wise (for single use sealed pack)	Brand name	Price to Retailer (PTR) for October, 2023	MAT* Sales Value as on October, 2023 (Rs.)

Please insert additional rows (if required).

^{*}Moving Annual Turnover (MAT) sales (excluding taxes) for October, 2023 means total sales during November, 2022 to October, 2023.

^{**} In case any company has been given separate ceiling price for non-glass with special features, the details may be provided in a separate table under above heads.

Table 2

S. No.	Formulations	Dosage form and Strength		
1	Glucose	Injection 5%		
		Injection 10%		
		Injection 50%		
2	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)		
3	Sodium Chloride	Injection 0.9% & 3%		
4		Injection (as per IP)		

2. The above mentioned information may be furnished within the stipulated period so that the ceiling prices are fixed in a transparent manner.

This is issued with the approval of competent Authority.

Yours faithfully,

(Mahaveer Saini)
Deputy Director
(pricing-NPPA@gov.in)

Copy to:

Apex Pharma Associations i.e. IDMA, IPA, OPPS, FOPE, FICCI, ASSOCHAM, FFSAI etc. for information and necessary action.